A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with ≤400/mm 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)

Fred T. Valentine, Smriti Kundu, Patrick A J Haslett, David Katzenstein, Laurel A Beckett, Cathie Spino, Michael Borucki, Margarita Vasquez, Gale Smith, Joyce Korvick, Jonathan Kagan, Thomas C. Merigan

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Immune responses provoked by human immunodeficiency virus (HIV) infection ultimately are insufficient to control the disease and do not include strong lymphocyte-proliferative responses to HIV antigens or antibodies to many vital epitopes. A randomized double-blind, placebo- controlled trial evaluated the immunogenicity of recombinant HIV envelope vaccine (rgp160) in HIV-infected subjects with ≤400/mm 3 CD4 T cells. Controls received hepatitis B vaccine. Of subjects receiving rgp160, 98% developed lymphocyte-proliferative responses to the immunogen, 33% to a different envelope protein, and 56% and 60% to p24 and p66, respectively. All doses of vaccine (20, 80, 320, 1280 μg) induced new responses. New antibodies to epitopes on rgp160 developed only in recipients of higher doses of rgp160. CD4 T cell percentages declined less rapidly in recipients of rgp160 than in controls. Vaccination of HIV-infected subjects with rgp160 results in cellular and humoral immune responses to HIV that infection itself had not stimulated.

Original languageEnglish (US)
Pages (from-to)1336-1346
Number of pages11
JournalJournal of Infectious Diseases
Volume173
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

Clinical Protocols
Acquired Immunodeficiency Syndrome
Vaccines
Placebos
Clinical Trials
HIV
T-Lymphocytes
Virus Diseases
Epitopes
Lymphocytes
Hepatitis B Vaccines
Antibodies
Humoral Immunity
Cellular Immunity
VaxSyn HIV-1 (gp160) vaccine
Vaccination
Antigens
Proteins

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with ≤400/mm 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). / Valentine, Fred T.; Kundu, Smriti; Haslett, Patrick A J; Katzenstein, David; Beckett, Laurel A; Spino, Cathie; Borucki, Michael; Vasquez, Margarita; Smith, Gale; Korvick, Joyce; Kagan, Jonathan; Merigan, Thomas C.

In: Journal of Infectious Diseases, Vol. 173, No. 6, 1996, p. 1336-1346.

Research output: Contribution to journalArticle

Valentine, FT, Kundu, S, Haslett, PAJ, Katzenstein, D, Beckett, LA, Spino, C, Borucki, M, Vasquez, M, Smith, G, Korvick, J, Kagan, J & Merigan, TC 1996, 'A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with ≤400/mm 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)', Journal of Infectious Diseases, vol. 173, no. 6, pp. 1336-1346.
Valentine, Fred T. ; Kundu, Smriti ; Haslett, Patrick A J ; Katzenstein, David ; Beckett, Laurel A ; Spino, Cathie ; Borucki, Michael ; Vasquez, Margarita ; Smith, Gale ; Korvick, Joyce ; Kagan, Jonathan ; Merigan, Thomas C. / A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with ≤400/mm 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). In: Journal of Infectious Diseases. 1996 ; Vol. 173, No. 6. pp. 1336-1346.
@article{02ac907b90ce401aa5d9ffc7993275e3,
title = "A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with ≤400/mm 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)",
abstract = "Immune responses provoked by human immunodeficiency virus (HIV) infection ultimately are insufficient to control the disease and do not include strong lymphocyte-proliferative responses to HIV antigens or antibodies to many vital epitopes. A randomized double-blind, placebo- controlled trial evaluated the immunogenicity of recombinant HIV envelope vaccine (rgp160) in HIV-infected subjects with ≤400/mm 3 CD4 T cells. Controls received hepatitis B vaccine. Of subjects receiving rgp160, 98{\%} developed lymphocyte-proliferative responses to the immunogen, 33{\%} to a different envelope protein, and 56{\%} and 60{\%} to p24 and p66, respectively. All doses of vaccine (20, 80, 320, 1280 μg) induced new responses. New antibodies to epitopes on rgp160 developed only in recipients of higher doses of rgp160. CD4 T cell percentages declined less rapidly in recipients of rgp160 than in controls. Vaccination of HIV-infected subjects with rgp160 results in cellular and humoral immune responses to HIV that infection itself had not stimulated.",
author = "Valentine, {Fred T.} and Smriti Kundu and Haslett, {Patrick A J} and David Katzenstein and Beckett, {Laurel A} and Cathie Spino and Michael Borucki and Margarita Vasquez and Gale Smith and Joyce Korvick and Jonathan Kagan and Merigan, {Thomas C.}",
year = "1996",
language = "English (US)",
volume = "173",
pages = "1336--1346",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with ≤400/mm 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)

AU - Valentine, Fred T.

AU - Kundu, Smriti

AU - Haslett, Patrick A J

AU - Katzenstein, David

AU - Beckett, Laurel A

AU - Spino, Cathie

AU - Borucki, Michael

AU - Vasquez, Margarita

AU - Smith, Gale

AU - Korvick, Joyce

AU - Kagan, Jonathan

AU - Merigan, Thomas C.

PY - 1996

Y1 - 1996

N2 - Immune responses provoked by human immunodeficiency virus (HIV) infection ultimately are insufficient to control the disease and do not include strong lymphocyte-proliferative responses to HIV antigens or antibodies to many vital epitopes. A randomized double-blind, placebo- controlled trial evaluated the immunogenicity of recombinant HIV envelope vaccine (rgp160) in HIV-infected subjects with ≤400/mm 3 CD4 T cells. Controls received hepatitis B vaccine. Of subjects receiving rgp160, 98% developed lymphocyte-proliferative responses to the immunogen, 33% to a different envelope protein, and 56% and 60% to p24 and p66, respectively. All doses of vaccine (20, 80, 320, 1280 μg) induced new responses. New antibodies to epitopes on rgp160 developed only in recipients of higher doses of rgp160. CD4 T cell percentages declined less rapidly in recipients of rgp160 than in controls. Vaccination of HIV-infected subjects with rgp160 results in cellular and humoral immune responses to HIV that infection itself had not stimulated.

AB - Immune responses provoked by human immunodeficiency virus (HIV) infection ultimately are insufficient to control the disease and do not include strong lymphocyte-proliferative responses to HIV antigens or antibodies to many vital epitopes. A randomized double-blind, placebo- controlled trial evaluated the immunogenicity of recombinant HIV envelope vaccine (rgp160) in HIV-infected subjects with ≤400/mm 3 CD4 T cells. Controls received hepatitis B vaccine. Of subjects receiving rgp160, 98% developed lymphocyte-proliferative responses to the immunogen, 33% to a different envelope protein, and 56% and 60% to p24 and p66, respectively. All doses of vaccine (20, 80, 320, 1280 μg) induced new responses. New antibodies to epitopes on rgp160 developed only in recipients of higher doses of rgp160. CD4 T cell percentages declined less rapidly in recipients of rgp160 than in controls. Vaccination of HIV-infected subjects with rgp160 results in cellular and humoral immune responses to HIV that infection itself had not stimulated.

UR - http://www.scopus.com/inward/record.url?scp=9444236148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444236148&partnerID=8YFLogxK

M3 - Article

C2 - 8648205

AN - SCOPUS:9444236148

VL - 173

SP - 1336

EP - 1346

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -